Department of Neurosurgery, Fuzhou General Hospital of Nanjing Command, Fuzhou, Fujian 350025, China.
Cell Immunol. 2011;269(2):144-8. doi: 10.1016/j.cellimm.2011.03.021. Epub 2011 Mar 24.
Heparanase has been proved as an promising tumor antigen for the therapeutical target. However, the antigen alone cannot fully elicit the immune response in vivo. In this study, Lewis X oligosaccharides-heparanase complex was prepared, which can target to the dendritic cells (DCs) via dendritic cell-specific intercellular-adhesion-molecule-grabbing non-integrin (DC-SIGN). In addition, the DCs were loaded with the complex, and then were utilized to immunize mice to detect the immune response. Our data demonstrated that the modified DCs could enhance the specific IFN-γ production and cytotoxic T cell response. Furthermore, the modified DCs could also significantly suppress the established tumor growth and prolong the life span of tumor-bearing mice. Therefore, the Lewis X oligosaccharides-heparanase complex might be regarded as an ideal vaccine, and represent a novel way for the therapeutical strategy of tumor.
肝素酶已被证明是一种有前途的治疗性肿瘤抗原。然而，仅抗原本身并不能在体内完全引发免疫反应。在这项研究中，制备了 Lewis X 寡糖-肝素酶复合物，它可以通过树突状细胞（DC）特异性细胞间黏附分子抓取非整联蛋白（DC-SIGN）靶向 DC。此外，负载有复合物的 DC 被用来免疫小鼠，以检测免疫反应。我们的数据表明，修饰后的 DC 可以增强特异性 IFN-γ 产生和细胞毒性 T 细胞反应。此外，修饰后的 DC 还可以显著抑制已建立的肿瘤生长并延长荷瘤小鼠的寿命。因此，Lewis X 寡糖-肝素酶复合物可能被视为一种理想的疫苗，并为肿瘤的治疗策略提供了一种新方法。
